Psoriasis Drugs: A Global Strategic Business Report
The psoriasis drugs market is expected to witness robust growth, as anti-TNF therapies continue to gain momentum. Enbrel and Humira are expected to drive the psoriasis drugs market through 2015. Nevertheless, factors expected to drive success of topical therapies include emergence of new, improved products in continuation of the existing therapies; introduction of new vehicles for topical drug delivery; and accessibility of Calcipotriol ointment. The world market for psoriasis drugs is projected to exceed $7.3 billion by the year 2015.
View full press release